CTX112 Trademark
CTX112 is a USPTO trademark filed by CRISPR Therapeutics AG. Status: Registered.
Trademark Facts
| Mark | CTX112 |
|---|---|
| Serial Number | 97371562 |
| Registration Number | 8137640 |
| Status | Registered |
| Filing Date | 2022-04-20 |
| Registration Date | 2026-02-10 |
| Mark Type | Word |
| Nice Classes | 005 (Pharmaceuticals), 042 (Software & IT) |
| Owner | CRISPR Therapeutics AG |
| Attorney of Record | Tiffany D. Gehrke |
| Prosecution Events | 54 |
| Latest Event | NRCC on 2026-02-10 |
Goods & Services
Cells for medical or clinical use in the field of CAR T cell therapy for the treatment of cancer and autoimmune diseases; pharmaceutical and biopharmaceutical agents for the treatment of cancer in the field of CAR T cell therapy; gene therapy products, namely, gene transfer, regulation, modulation and delivery pharmaceuticals for the treatment of cancer in the field of CAR T cell therapy; Gene editing, namely, medical and scientific research for the treatment of genetic diseases and disorders in the field of CAR T cell therapy for the treatment of cancer and autoimmune diseases; gene editing, namely, pharmaceutical research and development in the field of CAR T cell therapy for the treatment of cancer and autoimmune diseases
Recent Prosecution Activity
| Date | Document | Type |
|---|---|---|
| 2026-02-10 | Notice of Registration Email | ERO |
| 2026-02-10 | Registration Certificate | ORC |
| 2026-01-22 | TRAM Snapshot of App at Pub for Oppostn | PST |
| 2026-01-22 | Notice of Acceptance of SOU - E | ESO |
| 2026-01-06 | Amendment and Mail Process Complete | AMC |
| 2026-01-05 | Specimen | SPE |
USPTO Refusals on Record
- unacceptable_specimen